Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019

BURLINGAME, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and webcast on Thursday, May 9, 2019 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2019 financial results.  

The conference call can be accessed by dialing 1-800-479-1004 (toll-free domestic) or 1-720-543-0206 (international) and using the conference ID 5606517. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus' lead product candidate, ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter amended Phase 1b/2 clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of cifordenant both as a single agent and in combination with Genentech's atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. In May 2017, Corvus and Genentech expanded the collaboration and are now conducting a trial of cifordenant and atezolizumab in patients with NSCLC who have failed prior therapies with anti-PD-(L)1 and platinum-based chemotherapy. Corvus is evaluating a second product candidate, CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.

650-900-4522

LLea@corvuspharma.com

MEDIA CONTACT:

Sheryl Seapy

W2O pure 

213-262-9390

sseapy@w2ogroup.com

 

corvus_logo_small.jpg

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!